Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Meng, Xianmei ^a   Baylink, David J ^a   Sheng, Matilda ^a   Wang, Hongjie ^b   Gridley, Daila S ^a   Lau, K H William ^c   Zhang, Xiao Bing ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Jerry L Pettis Memorial VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BETA GLOBIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 2; STEM CELL ANTIGEN 1;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE TISSUE; CELL ENGINEERING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; ENDOSTEAL BONE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL GENE THERAPY; HYPOPHOSPHATEMIA; MOUSE; NONHUMAN; OSSIFICATION; OSTEOMALACIA; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; SPLEEN FOCUS FORMING VIRUS; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; TRABECULAR BONE;

ANIMALS; BETA-GLOBINS; BONE MARROW; FIBROBLAST GROWTH FACTOR 2; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; MICE; OSTEOGENESIS; OSTEOMALACIA; PROMOTER REGIONS, GENETIC;

ANIMALIA; MUS; SPLEEN FOCUS-FORMING VIRUS;

EID: 84862075829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037569     Document Type: Article

References (49)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
2. Lewiecki EM, (2010) Treatment of osteoporosis with denosumab. Maturitas 66: 182-186.
3. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, et al. (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25: 948-959.
4. Wang JS, (1996) Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Acta Orthop Scand Suppl 269: 1-33.
5. Nakamura K, Kawaguchi H, Aoyama I, Hanada K, Hiyama Y, et al. (1997) Stimulation of bone formation by intraosseous application of recombinant basic fibroblast growth factor in normal and ovariectomized rabbits. J Orthop Res 15: 307-313.
6. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, et al. (1995) Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136: 1276-1284.
7. Lane NE, Kumer J, Yao W, Breunig T, Wronski T, et al. (2003) Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int 14: 374-382.
8. Iwaniec UT, Magee KA, Mitova-Caneva NG, Wronski TJ, (2003) Bone anabolic effects of subcutaneous treatment with basic fibroblast growth factor alone and in combination with estrogen in osteopenic ovariectomized rats. Bone 33: 380-386.
9. Power RA, Iwaniec UT, Wronski TJ, (2002) Changes in gene expression associated with the bone anabolic effects of basic fibroblast growth factor in aged ovariectomized rats. Bone 31: 143-148.
10. Yao W, Hadi T, Jiang Y, Lotz J, Wronski TJ, et al. (2005) Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 16: 1939-1947.
11. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, et al. (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105: 1085-1093.
12. Lane NE, Yao W, Kinney JH, Modin G, Balooch M, et al. (2003) Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res 18: 2105-2115.
13. Hall SL, Lau KH, Chen ST, Wergedal JE, Srivastava A, et al. (2007) Sca-1(+) hematopoietic cell-based gene therapy with a modified FGF-2 increased endosteal/trabecular bone formation in mice. Mol Ther 15: 1881-1889.
14. Hall SL, Chen ST, Gysin R, Gridley DS, Mohan S, et al. (2009) Stem cell antigen-1+ cell-based bone morphogenetic protein-4 gene transfer strategy in mice failed to promote endosteal bone formation. J Gene Med 11: 877-888.
15. Chada K, Magram J, Raphael K, Radice G, Lacy E, et al. (1985) Specific expression of a foreign beta-globin gene in erythroid cells of transgenic mice. Nature 314: 377-380.
16. Chasis JA, Mohandas N, (2008) Erythroblastic islands: niches for erythropoiesis. Blood 112: 470-478.
17. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, et al. (2009) Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 17: 245-252.
18. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318-322.
19. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
20. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, et al. (2009) Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
21. Meng X, Neises A, Su RJ, Payne KJ, Ritter L, et al. (2011) Efficient Reprogramming of Human Cord Blood CD34(+) Cells Into Induced Pluripotent Stem Cells With OCT4 and SOX2 Alone. Mol Ther.
22. Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, et al. (2005) Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn 233: 115-121.
23. Mazue G, Bertolero F, Garofano L, Brughera M, Carminati P, (1992) Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). Toxicol Lett 64-65 Spec No: 329-338.
24. Nagai H, Tsukuda R, Mayahara H, (1995) Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16: 367-373.
25. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, et al. (2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201: 1781-1791.
26. Nakayama T, Mutsuga N, Tosato G, (2007) FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood 109: 1363-1372.
27. Iwaniec UT, Mosekilde L, Mitova-Caneva NG, Thomsen JS, Wronski TJ, (2002) Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology 143: 2515-2526.
28. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505.
29. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 1656-1663.
30. de Menezes Filho H, de Castro LC, Damiani D, (2006) Hypophosphatemic rickets and osteomalacia. Arq Bras Endocrinol Metabol 50: 802-813.
31. Juppner H, Wolf M, Salusky IB, (2010) FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res 25: 2091-2097.
32. Zhang XB, Schwartz JL, Humphries RK, Kiem HP, (2007) Effects of HOXB4 overexpression on ex vivo expansion and immortalization of hematopoietic cells from different species. Stem Cells 25: 2074-2081.
33. Martin I, Muraglia A, Campanile G, Cancedda R, Quarto R, (1997) Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 138: 4456-4462.
34. Walsh S, Jefferiss C, Stewart K, Jordan GR, Screen J, et al. (2000) Expression of the developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1-4. Bone 27: 185-195.
35. Baddoo M, Hill K, Wilkinson R, Gaupp D, Hughes C, et al. (2003) Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 89: 1235-1249.
36. Bianchi G, Banfi A, Mastrogiacomo M, Notaro R, Luzzatto L, et al. (2003) Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res 287: 98-105.
37. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, et al. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117: 2766-2777.
38. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED, (2007) Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 75: 831-842.
39. Barde I, Laurenti E, Verp S, Wiznerowicz M, Offner S, et al. (2011) Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther 18: 1087-1097.
40. Santilli G, Almarza E, Brendel C, Choi U, Beilin C, et al. (2011) Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 19: 122-132.
41. Bergwitz C, Juppner H, (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61: 91-104.
42. Silver J, Naveh-Many T, (2010) FGF23 and the parathyroid glands. Pediatr Nephrol 25: 2241-2245.
43. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, et al. (2010) Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem 285: 2834-2846.
44. Martin A, Liu S, David V, Li H, Karydis A, et al. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 25: 2551-2562.
45. Chen ST, Gysin R, Kapur S, Baylink DJ, Lau KH, (2007) Modifications of the fibroblast growth factor-2 gene led to a marked enhancement in secretion and stability of the recombinant fibroblast growth factor-2 protein. J Cell Biochem 100: 1493-1508.
46. Yam PY, Li S, Wu J, Hu J, Zaia JA, et al. (2002) Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 5: 479-484.
47. Wang H, Shayakhmetov DM, Leege T, Harkey M, Li Q, et al. (2005) A Capsid-Modified Helper-Dependent Adenovirus Vector Containing the β-Globin Locus Control Region Displays a Nonrandom Integration Pattern and Allows Stable, Erythroid-Specific Gene Expression. Journal of Virology 79: 10999-11013.
48. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, et al. (2011) Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 19: 479-489.
49. Sheng MH, Baylink DJ, Beamer WG, Donahue LR, Lau KH, et al. (2002) Regulation of bone volume is different in the metaphyses of the femur and vertebra of C3H/HeJ and C57BL/6J mice. Bone 30: 486-491.